(Q74348272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

M P Nair

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M R Nampoory

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

K V Johny

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

J N Costandi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Abdulhalim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

W El-Reshaid

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

I Al-Muzairai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

V T Ninan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Samhan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Al-Mousawi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 August 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

Transplantation Proceedings

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

2767-2769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

The use of antibodies against the IL-2 receptor in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

A review of interleukin-2 receptor antagonists in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

1 reference

7 January 2021

Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Can antibody prophylaxis allow sparing of other immunosuppressives?

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2902184-4

7 January 2021

10.1016/S0041-1345(01)02184-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11498153%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference